Athlete
Conditions
Brief summary
The aims of the study are 1) to compare the differences in plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances in athletes (i.e., soccer, and taekwondo players) and healthy non-athletes; 2) to investigate the relationship between plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances; 3) to explore the influence on plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances after 12 weeks of coenzyme Q10 intervention (150 mg/day and 300 mg/day).
Detailed description
The long-term high-amount and -intensity exercise training could cause oxidative damage, muscle impairment, inflammation and exercise fatigue to athletes easily. Such above conditions will affect the exercise performances and health of athletes. The aims of the study are 1) to compare the differences in plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances in athletes (i.e., soccer, and taekwondo players) and healthy non-athletes; 2) to investigate the relationship between plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances; 3) to explore the influence on plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances after 12 weeks of coenzyme Q10 intervention (150 mg/day and 300 mg/day). Eventually, these results of this study can provide the information for the known to improve the oxidative stress, anti-oxidation and inflammation internal to the bodies of athletes for various competitions. As a consequence, the athletic performances can be further enhanced.
Interventions
DIETARY_SUPPLEMENTCoenzyme Q10
150 mg or 300 mg
OTHERPlacebo
Placebo (dextrin)
Sponsors
Chung Shan Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Caregiver)
Intervention model description
placebo-control
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Athletes (soccer and taekwondo players)
Exclusion criteria
* Antioxidant vitamins users * Statins or Aspirin therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| malondialdehyde (MDA) | 12 weeks | MDA (micromol/L) will measure by thiobarbituric acid reacting substance. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| high sensitivity C-reactive protein (hs-CRP) | 12 weeks | hs-CRP will measure by immunoturbidimetry. |
| creatine kinase (CK) | 12 weeks | serum CK will measure by enzymatic method. |
| Lactate dehydrogenase (LDH) | 12 weeks | serum LDH will measure by enzymatic method. |
| Antioxidant capacity | 12 weeks | Total antioxidant capacity (TAC) was measured by a Trolox equivalent antioxidant capacity assay in serum and erythrocytes. |
| Glucose | 12 weeks | mmol/L |
| HbA1C | 12 weeks | HbA1C will measure by an automated glycated hemoglobin analyzer |
| Insulin | 12 weeks | insulin will measure by an automated chemistry analyzer |
| one-repetition maximum (1-RM) | 12 weeks | 1RM measurements will report in kilograms for data analysis. |
Countries
Taiwan
Outcome results
None listed